← All Sponsors
SPONSOR

Lazaros Lekakis

Total Trials
1
Recruiting
1
Phases
Phase 2
Conditions studied: Refractory Non-Hodgkin LymphomaRelapsed Non Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma
NCT05260957 Phase 2
Recruiting

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Refractory Non-Hodgkin Lymphoma
United States View Trial →